<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To evaluate the value of KRAS codon 13 mutations in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) treated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and fluoropyrimidines </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> specimens from 201 patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> from a randomized, phase III trial comparing <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>/5-FU vs. <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>/<z:chebi fb="0" ids="31348">capecitabine</z:chebi> were retrospectively analyzed for KRAS mutations </plain></SENT>
<SENT sid="2" pm="."><plain>Mutation data were correlated to response data (Overall response rate, ORR), progression-free survival (PFS) and overall survival (OS) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: 201 patients were analysed for KRAS mutation (61.2% males; mean age 64.2 ± 8.6 years) </plain></SENT>
<SENT sid="4" pm="."><plain>KRAS mutations were identified in 36.3% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (28.8% in codon 12, 7.4% in codon 13) </plain></SENT>
<SENT sid="5" pm="."><plain>The ORR in codon 13 patients compared to codon 12 and <z:mp ids='MP_0002169'>wild type</z:mp> patients was significantly lower (p = 0.008) </plain></SENT>
<SENT sid="6" pm="."><plain>There was a tendency for a better overall survival in KRAS <z:mp ids='MP_0002169'>wild type</z:mp> patients compared to mutants (p = 0.085) </plain></SENT>
<SENT sid="7" pm="."><plain>PFS in <z:hpo ids='HP_0000001'>all</z:hpo> patients was not different in the three KRAS genetic groups (p = 0.72) </plain></SENT>
<SENT sid="8" pm="."><plain>However, we found a marked difference in PFS between patients with codon 12 and 13 mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> treated with infusional 5-FU versus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> based regimens </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Our data suggest that the type of KRAS mutation may be of clinical relevance under <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> combination chemotherapies without the addition of monoclonal antibodies in particular when overall response rates are important </plain></SENT>
<SENT sid="10" pm="."><plain>TRIAL REGISTRATION NUMBER: 2002-04-017 </plain></SENT>
</text></document>